PDS Biotechnology (PDSB) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results
May 11, 2022 7:00 AM EDTFLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune® and Infectimune T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call... More
